... 3a individuals. Methods: The patients were given antiviral therapy with IFN-α-2b, 3 million units 3 times a week and 800-1,200 mg of ribavirin daily adjusted to the patient's body weight (<60 kg 800 mg day− 1 , and >60 kg 1,200 day− 1 ). The patients received this combination therapy for 24...

... (HCV-6) patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). Methods: Data were retrieved from Medline, Embase, PubMed and the Cochrane Library for ‘genotype 6' studies published up to December 2014 and for abstracts from international scientific meetings. Inclusion criteria were...

... patients, those coinfected experience decreased spontaneous HCV clearance, accelerated liver fibrosis, and a decreased response to anti-HCV therapy. We conducted a meta-analysis to estimate the efficacy of treating acute HCV in HIV-positive patients with peginterferon and ribavirin combination therapy...

... was considered statistically significant. 5′-CCCGTCCATGTGTAGGACAT-3′ (outer, antisense primer), 5′-GGGTCACAGCTCCCTGTGAGCC-3′ (inner, sense primer) and 5′-GAGGGTTGTAATCCGGGCGTGC-3′ (inner, antisense primer). Chronic hepatitis C Peginterferon Ribavirin Reduction in HCV RNA levels Early...

...Tanja Selic Kurincic; Gorazd Lesnicar; Mario Poljak; Jelka Meglic Volkar; Mojca Rajter; Janja Prah; Zvonko Baklan; Tadeja Kotar; Mojca Maticic Objectives: The combination of pegylated interferon-α and ribavirin is a standard-of-care (SOC) treatment for chronic hepatitis C (CHC), and it achieves...

...Hyun Jung Chung; Jin-Woo Lee; Young Soo Kim; Jung Il Lee Objectives: The aim of this study was to evaluate rapid virologic response (RVR) rate after peginterferon (PegIFN) and ribavirin (RBV) dual combination therapy in Korean hepatitis C virus (HCV) genotype 1 patients whose IL28B polymorphism...

...Norio Akuta; Fumitaka Suzuki; Yuya Seko; Yusuke Kawamura; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada Objective: Anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus...

... (HCV) genotype 1b (HCV-1b) is an important predictor of hepatocellular carcinoma (HCC), but its impact on HCC in nonresponders to interferon (IFN) and ribavirin (RIB) combination therapy is not clear. Methods: A total of 292 patients with HCV-1b-related chronic liver disease who did not achieve...

... the IL28B gene and substitution of aa 70 and 91 in the core region of HCV-1b are useful as predictors of treatment efficacy to telaprevir/pegylated interferon (PEG-IFN)/ribavirin, but its impact on viral dynamics is not clear. Methods: This study investigated predictive factors of viral dynamics during 12...

... efficacy to interferon (IFN)/ribavirin in patients infected with HCV genotype 1b (HCV-1b). Methods: This study investigated pretreatment predictors, including viral- (aa substitutions in core aa 70/91 and NS5A-ISDR/IRRDR) and host-related factors (genetic variation near IL28B gene), to 48-week IFN...

... thereafter, he received IFN-α 3 MU daily for 2 weeks and then 3 times a week for 14 weeks combined with oral ribavirin 600 mg daily during 16 weeks. HCV RNA disappeared from the serum and stayed negative until the last follow-up 24 weeks after the completion of combination therapy. Chimpanzee Hepatitis C...

... hepatitis C the suitable treatment duration is still unclear. The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2. Methods: 7 patients infected with genotype 2 at a high viral load and who did not achieve a sustained virological response (SVR...

... in LILs. Conclusion: The evaluation of Tregs, a potentially significant factor for persistent HCV infection, in LILs prior to treatment and in PBMCs during treatment could predict the result of combination therapy. Chronic hepatitis C Hepatitis C virus Interferon Ribavirin Regulatory T cells ©...

...Seok Lee; In Hee Kim; Seong Hun Kim; Sang Wook Kim; Seung Ok Lee; Soo Teik Lee; Dae Ghon Kim; Chang Seop Lee; Chang Soo Choi; Eun Young Cho; Haak Cheoul Kim Objectives: The authors compared the efficacies and tolerabilities of pegylated interferon-α 2a (PEG-IFN-α 2a ) + ribavirin and pegylated...

...-IFN) and ribavirin (RBV) combination therapy for chronic hepatitis C (CHC) and examined its correlation with serum alanine aminotransferase (ALT) levels during therapy and response to the therapy. Methods: A total of 175 patients with CHC received the combination therapy. Correlations between serum...

... had high viral load were treated with pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy. We retrospectively analyzed 10 ULVR who received extended combination treatment beyond 48 weeks. Results: The duration of the combination treatment for ULVR ranged between 59 and 119 weeks...

...I.S. Elefsiniotis; E. Vezali; C. Mihas; G. Saroglou Objectives: To investigate early viral kinetics, sustained virological response (SVR) rates and their predictors, in treatment-naïve, genotype-4-infected, chronic hepatitis C (CHC) patients treated with PEG-IFNα2b plus ribavirin. Patients...

... region of HCV genotype 1b is a useful pretreatment predictor of poor response to interferon + ribavirin combination therapy, but the impacts of aa substitutions in the core region of HCV genotype 2a are still not clear. Methods: 154 consecutive Japanese adults with a high viral load (≥100 kIU/ml...

...Hitomi Sezaki; Fumitaka Suzuki; Norio Akuta; Hiromi Yatsuji; Tetsuya Hosaka; Masahiro Kobayashi; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada Objective: Response to pegylated (PEG) interferon (IFN) and ribavirin is achieved only in 40–50% of patients infected...

...William O. Dawson; Hector Lozoya-Saldana Ribavirin inhibited a specific step of tobacco mosaic virus (TMV) replication. Time-courses of sensitivity of TMV multiplication in asynchronous and synchronous infections demonstrated that ribavirin inhibited an early function that occurs prior...